Our group has previously observed that the vast majority of patients with TN and HER2+ breast cancer are seen first by a surgeon following diagnosis, highlighting the surgeon–medical oncologist referral pathway as an important target for further study [2]. Here, ERBB2 is linked to breast carcinoma.